title: Clinical results of 24 pituitary macroadenomas with linac-based stereotactic radiosurgery.
abstract: OBJECTIVE
  To determine the impact of stereotactic radiosurgery (SRS) on the clinical course, hormonal status, and follow-up CT/MRI scan of pituitary macroadenomas.
  
  
  METHODS
  From July 1988 to March 1996, 24 pituitary macroadenomas had been treated using 6 MV linear accelerator based SRS. They consisted of 11 (45.8%) prolactinomas, 2 (8.3%) growth hormone (GH)-secreting tumors, 1 (4.2%) Cushing's disease, 8 (33.3%) nonsecreting (nonfunctioning: NF) tumors, and 2 (8.3%) mixed prolactin-growth hormone (PRL-GH)-secreting tumors (M:F = 12:12; aged 21-61 years). Postoperative irradiation was performed in all cases except for the instance of Cushing's disease. The prescribed dose to tumor center varied from 10 to 27 Gy (mean 21.1 Gy) using a collimator size of 0.5 to 2.5 cm. The follow-up duration ranged from 13 to 89 months (mean 49.2 months). Results from these patients were compared to our results using conventional radiation.
  
  
  RESULTS
  Visual acuity and field defect were improved or became normal in 19 (79.2%) cases. Four (16.7%) remained unchanged after the treatment. One (4.1%) progressed 6 years after SRS and subsequently had repeat surgery with conventional boost irradiation. Of the 13 (46.4%) prolactinomas, including two mixed PRL-GH secreting tumors, 11 (84.1%) revealed normal hormonal levels within 1 year after SRS. In contrast, it took 2 years to become normal after conventional radiation therapy. In four GH-secreting tumors including two mixed PRL-GH secreting tumors, SRS and conventional methods showed similar responses. On follow-up imagings of the 21 patients, the mass was completely resolved in 4 (16.7%), including 3 PRLs and one NF, decreased in 11 (45.8%), and unchanged in 5 (16.7%) with central necrosis or cysts. One (4.2%) progressed and was reoperated 6 years after treatment. The complications related to SRS were comparable to those from conventional method.
  
  
  CONCLUSIONS
  Radiosurgery can be used effectively in patients with pituitary adenoma. In this study, a more rapid hormonal and clinical response was achieved with radiosurgery than with conventional pituitary irradiation treatment.
authors.affiliation: Department of Therapeutic Radiology, Catholic University, Kangnam St. Mary's Hospital & Cancer Center, Seoul, Korea.
authors.forename: S C
authors.initials: SC
authors.lastname: Yoon
authors.forename: T S
authors.initials: TS
authors.lastname: Suh
authors.forename: H S
authors.initials: HS
authors.lastname: Jang
authors.forename: S M
authors.initials: SM
authors.lastname: Chung
authors.forename: Y S
authors.initials: YS
authors.lastname: Kim
authors.forename: M R
authors.initials: MR
authors.lastname: Ryu
authors.forename: K H
authors.initials: KH
authors.lastname: Choi
authors.forename: H Y
authors.initials: HY
authors.lastname: Son
authors.forename: M C
authors.initials: MC
authors.lastname: Kim
authors.forename: K S
authors.initials: KS
authors.lastname: Shinn
mesh_terms: D000236:Adenoma / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D015175:Prolactinoma / Q000097:blood / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D016634:Radiosurgery; D012189:Retrospective Studies; D014792:Visual Acuity; D014794:Visual Fields
chemical_list: D013006:Growth Hormone